Radnostix Inc
RADNOSTIX INC is part of a U.S.-based nuclear medicine and isotope business that manufactures calibration and reference standards, radiochemical products, and cobalt-based source products. Its operations span medical, industrial, and research applications, with products distributed in the United States and internationally through company facilities and subsidiaries.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRadiopharmaceuticals, APIs, and radiochemicals used in medical, industrial, and research settings.
Bulk cobalt-60, sealed sources, capsule fabrication, and source recycling services.
Calibration and reference standards and related quality-control products for imaging workflows.
Quality-control and calibration devices sold through RadQual and related channels.
Customers
Customers include medical device makers, radiopharmaceutical developers, hospitals and imaging centers, and research organizations that need isotope-based materials or calibration products. The company also serves industrial users that incorporate cobalt products into radiation therapy or other specialized applications. Buyers are typically seeking regulated, specialized inputs that are difficult to source domestically or require precise specifications.
Buy isotopically pure radiopharmaceuticals, APIs, and radiochemicals for therapy and imaging products.
Buy calibration and reference standards plus QC devices to validate imaging systems and workflows.
Buy cobalt-60 products and sealed sources for therapy, industrial, and medical applications.
Buy radioisotopes for clinical trials and research programs that later feed approved products.
Strategy
The company is focused on specialized isotope and cobalt products where regulatory capability, licensing, and supply reliability create barriers to entry. It is also building a stronger role in theranostics and radiopharmaceutical supply by offering customized products and domestic alternatives to imported sources. Maintaining access to reactor-based feedstock and distributor relationships is central to preserving its market position.
These products sit in a growing medical isotope market and require specialized capabilities.
The business depends on just-in-time radioisotope inputs that cannot be stockpiled easily.
Domestic production and unique licensing can differentiate the company from foreign suppliers.
Geography
Q3/2024The company is based in the United States and can ship products to all 50 states, while also serving international customers. Its isotope and cobalt supply chain is tied to specialized U.S. facilities and reactors, which makes domestic sourcing and logistics central to operations. The business also includes a China joint venture within its theranostics activities, adding an international operating element.
Share of the revenue the company reports by geography.
Risks
The business is exposed to supply-chain disruption because radioisotopes are sourced through specialized reactors and logistics networks that cannot be easily buffered with inventory. It also faces regulatory, distributor, and customer-concentration risk because its products are highly specialized and often tied to FDA, NRC, and DOE requirements. Broader industry risks include raw-material inflation, energy costs, and the possibility that alternative suppliers or reactor outages interrupt sales.
- Radioisotope supply interruptionImpact: HighLikelihood: High
The company relies on just-in-time inputs from specialized reactors and suppliers.
Exposure - Regulatory and licensing dependenceImpact: HighLikelihood: High
Operations depend on NRC, FDA, DOE, and transport approvals for production and shipment.
Exposure: All isotope-related segments
- Input cost inflationImpact: MediumLikelihood: Medium
Raw materials, utilities, energy, and infrastructure costs are not fully controllable.
Exposure: Manufacturing and logistics
- Distributor and channel disruptionImpact: MediumLikelihood: Low
Loss of territorial distributors could reduce access to end customers.
Exposure: International and regional sales
Accounting
Judgemental itemsOrders may be recognized when shipped or delivered, creating quarterly volatility.
Impact: Affects reported sales and comparability across periods
Disposal of non-core assets can create gains, cash proceeds, and liability reductions.
Impact: Can materially affect income statement and balance sheet
Acquisition-related notes require principal and interest tracking over time.
Impact: Affects debt balance and interest expense
Niche facilities and equipment may lose value if projects are paused or exited.
Impact: Could trigger write-downs or gains/losses on sale
Similar listed companies
Publicly listed companies with a comparable business focus.
Radiopharm Theranostics Ltd
RDPTF · Pharmaceutical Preparations
Radiopharm Theranostics Ltd is an Australia-based clinical-stage radiopharmaceutical company developing diagnostic and therapeutic products for cancer.
Telix Pharmaceuticals Ltd
TLX · Pharmaceutical Preparations
Telix Pharmaceuticals Ltd is an Australia-headquartered biopharmaceutical company that develops and commercializes radiopharmaceuticals for oncology and rare disease applications.
RadNet, Inc.
RDNT · Services-Medical Laboratories
Vivos Inc
RDGL · Surgical & Medical Instruments & Apparatus
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Autonomix Medical, Inc.
AMIX · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026